Vorinostat Approved in Japan for Treatment of Cutaneous T-Cell Lymphomas: Status and Prospects

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s23874
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Benefits of Vorinostat in Treating Advanced Cutaneous T-Cell Lymphoma

Oncology & Hematology Review (US)
2009English

An Overview of Cutaneous T Cell Lymphomas

F1000Research
GeneticsMolecular BiologyPharmacologyBiochemistryMicrobiology ImmunologyMedicineToxicologyPharmaceutics
2016English

Pegylated Liposomal Doxorubicin in the Treatment of Primary Cutaneous T-Cell Lymphomas

Haematologica
Hematology
2007English

Trends in the Treatment of Cutaneous T-Cell Lymphoma &Ndash; Critical Evaluation and Perspectives on Vorinostat

Blood and Lymphatic Cancer: Targets and Therapy
2012English

Vorinostat for the Treatment of Bullous Pemphigoid in the Setting of Advanced, Refractory Cutaneous T-Cell Lymphoma

Archives of Dermatology
2009English

Japanese Guidelines for Cutaneous Lymphomas: Cutaneous Adult T Cell Leukemia/Lymphoma (ATLL)

Skin Cancer
2008English

Cutaneous T-Cell Lymphomas: Modern Data of Pathogenesis, Clinics and Therapy

Oncogematologiya
OncologyHematology
2018English

Potentials of Brentuximab Vedotin in the Treatment of Relapse/Refractory Cutaneous T-Cell Lymphomas: Literature Review and Authors’ Observation

Vestnik dermatologii i venerologii
2019English

EPIDEMIOLOGICAL AND HUMANISTIC BURDEN OF CUTANEOUS T-Cell LYMPHOMAS: RESULTS OF a SYSTEMATIC REVIEW

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy